Is adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysis

Gray, Richard; Bressington, Daniel; Ivanecka, Ada; Hardy, Sheila; Jones, Martin; Schulz, Michael; Bormann, Suparpit von; White, Jacquie; Anderson, Kathryn H.; Chien, Wai Tong

doi:10.1186/s12888-016-0801-1

Cited by 44 publications

(46 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While this intervention showed some early promise for improving insight, adherence, attitudes towards medication and rehospitalisation rates in an inpatient sample (Kemp et al, 1996(Kemp et al, , 1998, further studies failed to replicate these positive findings for improving adherence (Barkhof et al, 2013;Byerly et al, 2005;O'Donnell et al, 2003), and a well-conducted, adequately powered RCT found adherence therapy to be ineffective in improving adherence, psychotic symptoms or quality of life in people with schizophrenia (Gray et al, 2006). Some evidence for efficacy has been provided by subsequent studies (Chien et al, 2019;Gray et al, 2016;Wong-Anuchit et al, 2019), although this generally relates to improving psychiatric symptoms rather than adherence directly.…”

Section: Interventions To Improve Adherencementioning

confidence: 99%

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology

2019

View full text Add to dashboard Cite

These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, involving experts in schizophrenia and its treatment.They were asked to review key areas and consider the strength of the evidence on the risk-benefit balance of pharmacological interventions and the clinical implications, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials where available, plus updates on current clinical practice. The guidelines cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. It is hoped that the practice recommendations presented will support clinical decision making for practitioners, serve as a source of information for patients and carers, and inform quality improvement.

show abstract

Section: Interventions To Improve Adherencementioning

confidence: 99%

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology

2019

View full text Add to dashboard Cite

show abstract

“…Отдельный интерес представляет влияние на эффективность терапии РА шизотипического расстройства, поскольку ранее, насколько нам известно, влияние этого фактора не оценивалось. В то время как о распространенности шизотипического расстройства в популяции больных РА практически ничего не известно, данные ряда исследований демонстрируют низкую (<50%) приверженность людей с этим диагнозом лечению антипсихотическими препаратами и антидепрессантами [49,50]. В отсутствие иных данных можно допустить, что представленное наблюдение распространяется и на приверженность противоревматической терапии.…”

Section: таблица 6aunclassified

Factors Influencing the Efficiency of Therapy in Patients With Rheumatoid Arthritis: The Role of Comorbid Mental and Somatic Diseases

Абрамкин¹,

Лисицына²,

Veltishchev³

et al. 2018

rsp

View full text Add to dashboard Cite

The response rate to therapy for rheumatoid arthritis (RA) rarely exceeds 60%. Mental disorders (MDs) of the anxiety-depressive spectrum (ADS) and cognitive impairment (CI) substantially affect the evaluation of the efficiency of RA therapy. Adequate psychopharmacotherapy is one of the possible approaches to optimizing the treatment of RA. The factors influencing the efficiency of RA therapy with standard disease-modifying antirheumatic drugs (DMARDs) and biological agents (BAs) in combination with adequate psychopharmacotherapy have not been previously identified. Objective: to determine the predictors of response to therapy in patients with RA receiving DMARDs and BAs with or without adequate psychopharmacotherapy for ADS disorders. Subjects and methods. The investigation included 128 patients (13% men and 87% women) with a reliable diagnosis of RA. At baseline, 75.1% of patients received DMARDs; 7.8% – BAs. ADS disorders were detected in 123 (96.1%) patients. Psychopharmacotherapy was offered to all the patients with MDs; 52 patients agreed to treatment and 71 refused. The following therapeutic groups were identified according to the performed therapy: 1) DMARDs (n = 39); 2) DMARDs + psychopharmacotherapy (n = 43); 3) DMARDs + BAs (n = 32); 4) DMARDs + BAs + psychopharmacotherapy (n = 9). The changes of MDs symptoms and the outcomes of RA were assessed in 83 (67.5%) patients at five-year follow-up. The efficiency of RA therapy was evaluated with DAS28 (EULAR criteria). Predictors of response to therapy were determined using linear regression modeling. Results and discussion. At 5 years, 22 (26.5%) and 37 (44.6%) patients were recorded to show good and moderate responses to therapy, respectively; 24 (28.9%) patients were non-respondents. The linear regression model included 14 factors (p<0.001). The high values of DAS28 (β=0.258) at the inclusion; belonging to therapeutic groups 2 (β=0.267), 3 (β=0.235), and 4 (β=0.210), the absence of diabetes mellitus (β=-0.230), and experience in using glucocorticoids (β=-0.230) were associated with a high likelihood of response to therapy; high body mass index (β=-0.200) and long RA duration (β=-0,181), a high level of rheumatoid factor (β=-0.176), a history of myocardial infarction (β=-0.153), schizotypic disorder (β=-0.132), and extra-articular manifestations of RA (β=-0.106), and older age (β=-0.102) were related to a low probability of response. The area under the ROC curve for the model was 0.99 (p><0.001). Conclusion. BA therapy and psychopharmacotherapy, along with younger age, shorter duration and high activity of RA, a low level of rheumatoid factor, lower body mass index, the absence of diabetes mellitus, myocardial infarction, and extra-articular manifestations of RA in the history, schizotypic disorder, and experience in using glucocorticoids are associated with a greater likelihood of a good and moderate treatment response. Keywords: rheumatoid arthritis; mental disorders; disease-modifying antirheumatic drugs; biological agents; efficiency of therapy; predictors; psychopharmacotherapy; therapy adherence><0.001). The high values of DAS28 (β=0.258) at the inclusion; belonging to therapeutic groups 2 (β=0.267), 3 (β=0.235), and 4 (β=0.210), the absence of diabetes mellitus (β=-0.230), and experience in using glucocorticoids (β=-0.230) were associated with a high likelihood of response to therapy; high body mass index (β=-0.200) and long RA duration (β=-0,181), a high level of rheumatoid factor (β=-0.176), a history of myocardial infarction (β=-0.153), schizotypic disorder (β=-0.132), and extra-articular manifestations of RA (β=-0.106), and older age (β=-0.102) were related to a low probability of response. The area under the ROC curve for the model was 0.99 (p<0.001). Conclusion. BA therapy and psychopharmacotherapy, along with younger age, shorter duration and high activity of RA, a low level of rheumatoid factor, lower body mass index, the absence of diabetes mellitus, myocardial infarction, and extra-articular manifestations of RA in the history, schizotypic disorder, and experience in using glucocorticoids are associated with a greater likelihood of a good and moderate treatment response. Keywords: rheumatoid arthritis; mental disorders; disease-modifying antirheumatic drugs; biological agents; efficiency of therapy; predictors; psychopharmacotherapy; therapy adherence><0.001). Conclusion. BA therapy and psychopharmacotherapy, along with younger age, shorter duration and high activity of RA, a low level of rheumatoid factor, lower body mass index, the absence of diabetes mellitus, myocardial infarction, and extra-articular manifestations of RA in the history, schizotypic disorder, and experience in using glucocorticoids are associated with a greater likelihood of a good and moderate treatment response.

show abstract

“…Although it is important to evaluate these programs after implementation to determine the effectiveness of the program, many of these programs do not have an evaluation scale 8,9 . One program that has an evaluation scale is the Illness Management and Recovery (IMR) program, which focuses on managing the illness and recovery of individuals with mental disorders, preventing relapses, and achieving long‐term remission.…”

Section: Introductionmentioning

confidence: 99%

Psychometric properties of the Turkish version of Illness Management and Recovery Scale‐Patient form

Polat

Kutlu

Gültekin

2020

Perspect Psychiatr Care

View full text Add to dashboard Cite

Purpose: The aim of this study was to provide the Turkish version of the Illness Management and Recovery Scale-Patient (IMRS-P) form and to determine its psychometric properties. Design and Methods: This is a descriptive and correlation study. The sample of this study consisted of 75 people with schizophrenia. Translation and content validity, confirmatory factor analyses were used to test the validity and reliability of the scales. Results: The content validity index was found to be 0.93. The scale had a threefactor structure, which subscales were 0.69 for recovery, 0.69 for management, and 0.35 for substance. The Cronbach's alpha was determined as 0.76. Practice Implications: The Turkish version of the IMRS-P form is a valid and reliable scale for Turkish patients.

show abstract

Is adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysis

Cited by 44 publications

References 33 publications

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology

Factors Influencing the Efficiency of Therapy in Patients With Rheumatoid Arthritis: The Role of Comorbid Mental and Somatic Diseases

Psychometric properties of the Turkish version of Illness Management and Recovery Scale‐Patient form

Contact Info

Product

Resources

About